ArticleNeuropsychiatric disease and treatment2025
Neurologists' Openness to Evidence-Based Innovation in Multiple Sclerosis Care: Individual and Structural Determinants.
Article in Neuropsychiatric disease and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Personalizing Relapsing-Remitting Multiple Sclerosis Monitoring: Patient Acceptance of Serum Neurofilament Light Chain and the Role of Disease Knowledge.Journal of personalized medicine · 2026Article
- Behavioral barriers in the management of spinal muscular atrophy: The role of procrastination, regret, and burnout.PloS one · 2026Article
- Treatment Preferences of Neurologists in Generalized Myasthenia Gravis: A Conjoint Analysis Study.Neurology and therapy · 2025Article
- Large language models as clinical decision-support tools in multiple sclerosis and neuromyelitis optica spectrum disorders: A comparative study of ChatGPT-4o and neurologists.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Integration of evidence-based innovations, such as serum neurofilament light chain (sNfL) measurement into routine practice represents a pivotal opportunity to advance personalized care in multiple sclerosis (MS) management. This study assessed neurologists' openness to adopting healthcare innovations (sNfL testing), focusing on individual characteristics and structural factors like workplace environment and resources. Methods: An observational, cross-sectional study was conducted in partnership with the Spanish Society of Neurology. Neurologists caring for patients with MS completed an e-survey assessing openness to innovation using the Openness subscale of the Evidence-Based Practice Attitude Scale (EBPAS), alongside measures of empathy, healthcare-related regret, risk preferences, burnout, and workplace communication. Logistic and linear regression models were conducted to identify predictors of openness to innovation. Results: One hundred and sixteen neurologists were studied. Mean age (SD) was 41.9 (10.1) years, 53.4% were male. Mean experience as neurologists was 16.0 (9.2) years and 96.6% worked in an academic hospital. Median (IQR) EBPAS-Openness score was 3.0 (2.5-3.5), with 54.3% (n=63) of participants demonstrating openness to innovation. Participants fully dedicated to MS care, managing higher patient volumes, engaged in research publications, with access to serum neurofilament light chain testing, and a greater propensity for risk-taking, were more open to adopting innovations than their counterparts. Multivariate logistic regression analysis showed that access to sNfL testing and higher empathy levels were significant predictors of openness (OR=3.52, CI 95%: 1.3-10.3; p=0.016 and OR=1.09, CI 95%: 1.0-1.2; p=0.005, respectively). Complementary linear regression reinforced the significant positive association between higher EBPAS-Openness scores and empathy (estimate=0.024, p=0.001). Conclusion: Neurologists exhibited a varied openness to innovation. Implementing initial innovative strategies in clinical practice should prioritize neurologists with specific profiles to support the integration of emerging tools and personalized healthcare approaches in MS care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.